Skip to main content
. 2022 Nov 24;25(1):117–127. doi: 10.1002/ejhf.2728

Figure 5.

EJHF-2728-FIG-0005-c

Effect of empagliflozin by body mass index (BMI) as a continuous variable. Spline regression models showing the treatment effect of empagliflozin versus placebo across BMI as a continuous variable for (A) the primary endpoint, (B) first hospitalization for heart failure (HHF), (C) cardiovascular (CV) death, and (D) a histogram with BMI distribution. CI, confidence interval.